- Details
- James Wysock joins Zachary Klaassen to discuss improving prostate cancer diagnostics through better biopsy needle technology. Dr. Wysock highlights early experience with the SUREcore® Biopsy Needle from URO-1 Medical, which aims to enhance tissue collection quality, reduce core fragmentation, and improve diagnostic accuracy. He also discusses coreCARE® Specimen Retrieval for optimal tissue transfe...
|
- Details
- Andrea Miyahira hosts Jean Tien to discuss research on CDK12 in prostate cancer. Dr. Tien demonstrates that CDK12, a transcription-associated kinase mutated in approximately 7% of metastatic prostate cancers, functions as a tumor suppressor gene. Using mouse models, she shows CDK12 deletion leads to prostate hyperplasia and high-grade PIN lesions, with CDK12-null organoids displaying increased pro...
|
- Details
- Andrea Miyahira speaks with Brad Gallent about a paper on the structural biology of ONECUT2, a transcription factor highly expressed in advanced prostate cancer. Dr. Gallent presents work revealing the first crystal structure of ONECUT2, showing how its CUT and HOX subdomains function together to create high-affinity DNA binding. Through isothermal titration calorimetry and mutation studies, Dr. G...
|
- Details
- Andrea Miyahira speaks with Marina Sharifi about high-purity circulating tumor cell (CTC) RNA sequencing in prostate cancer. Dr. Sharifi describes a high-stringency CTC isolation approach that achieves tissue biopsy-comparable tumor purity from just a tablespoon of blood, enabling comprehensive transcriptional profiling to identify distinct lineage states. The multi-institutional study of 70 patie...
|
- Details
- Andrea Miyahira speaks with Lloyd Trotman about a dietary pro-oxidant treatment approach for prostate cancer. Dr. Trotman explains how the research was inspired by the surprising SELECT trial findings that antioxidant supplements increased prostate cancer risk by 17%. Testing the opposite approach, they found that menadione—a vitamin K precursor naturally found in green vegetables and fermented fo...
|
- Details
- Andrea Miyahira speaks with Lisa Chesner about the relationship between androgen receptor inhibition and MHC class I expression in prostate cancer. Dr. Chesner describes how her team used a whole-genome CRISPRi screen to identify the androgen receptor as a top regulator of MHC class I expression, with AR suppression significantly increasing MHC levels. She demonstrates that AR inhibition through e...
|
- Details
- Alicia Morgans is joined by Alan Dal Pra and George Zhao to discuss updates to the PORTOS Trial. PORTOS is a gene signature developed to predict radiation therapy benefit in prostate cancer, built on Veracyte's Decipher® platform using 24 genes to calculate radiation response. The signature has been validated in two randomized trials - SAKK 09/10 in the post-operative setting and RTOG 0126 in the...
|
- Details
- Varadha Balaji Venkadakrishnan joins Andrea Miyahira to discuss research examining EZH2's lineage-specific activity in advanced prostate cancer subtypes. His work explores how this histone modifier functions differently in neuroendocrine prostate cancer (NEPC) compared to adenocarcinoma, particularly in cases of treatment resistance and lineage plasticity. Through analysis of patient-derived model...
|
- Details
- Laura Sena discusses a case study illustrating how intratumoral heterogeneity drives therapy resistance in metastatic prostate cancer. Through detailed analysis of a patient's disease progression over seven years, Dr. Sena demonstrates how distinct cancer cell populations within the primary tumor led to treatment resistance through clonal selection rather than adaptation. The study reveals how the...
|
- Details
- Christopher Barbieri joins Andrea Miyahira to discuss research exploring how androgen receptor (AR) response elements function in prostate cancer. His team's work reveals distinct transcriptional programs controlled by AR, showing that canonical AR response elements actually suppress tumor growth while maintaining normal prostate cell differentiation. Using artificial transcription factors, the te...
|
